Company: STAA
Filing Date: 2025-12-08
Form Type: DFAN14A
Source: 0001213900-25-119309
Chunk: 2

Company: STAAR SURGICAL CO
Filing Date: 2025-12-08
Form: DFAN14A
Chunk 2
---
PLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE STOCKHOLDER MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The definitive proxy statement and an accompanying GREENProxy Card will be furnished to some or all of the Company’s stockholders and will be, along with other relevant documents, available at no charge on the SEC’s website at https://www.sec.gov/.

Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants with the SEC on November 21, 2025 and is available here.

Exhibit 1

<div align='center'>Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote “ AGAINST” Sale to Alcon

Egan-Jones Takes No Comfort From Perfunctory Go-Shop Process and Says Concerns Regarding Objectivity and Fairness Remain the Same</div>

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today announced that leading proxy advisory firm Egan-Jones Ratings Company (“Egan-Jones”) has reaffirmed its recommendation that shareholders vote “ AGAINST” the proposed acquisition of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) by Alcon Inc. (“Alcon”) (NYSE: ALC) on the GREENProxy Card.

Earlier today, the Company announced the completion of the belated, band-aid 30-day go-shop period and reiterated its support for the flawed transaction with Alcon despite the fact that the deal has drawn overwhelming opposition from shareholders and was opposed by all three leading proxy advisory firms.

In its report over the weekend, Egan-Jones recommended shareholders continue to vote against the transaction and said:

“For the same reasons as before, we are voting AGAINST the proposed merger of STAAR with Alcon. Although the merger agreement has been amended to include a go-shop provision and a revised termination fee, ultimately, we recommend against the merger due to the proposed valuation and the belief that STAAR’s standalone value is greater than what would be received in the proposed transaction. Additionally, we